In this issue of Metabolism, Omori et al [
[1]
] report that dapagliflozin, a sodium-glucose co-transporter-2 inhibitor (SGLT2i),
prevents hepatic steatosis (assessed by triglyceride liver content) after 8 weeks
of administration in db/db mice, a mouse model of obesity and diabetes.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Metabolism - Clinical and ExperimentalAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Nomoto H, et al.Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice, Metabolism2019 Jun 13 ([Epub ahead of print])
- Pharmacotherapy of type 2 diabetes: an update.Metabolism. 2018; 78: 13-42
- Sodium-glucose cotransporter 2 inhibitors (SGLT2i): their role in cardiometabolic risk management.Curr Pharm Des. 2017; 23: 1522-1532
- Antidiabetic drugs as antihypertensives: new data on the horizon.Curr Vasc Pharmacol. 2017; 16: 70-78
- Effects of newer antidiabetic drugs on endothelial function and arterial stiffness: a systematic review and meta-analysis.J Diabetes Res. 2018 Dec 4; 2018: 1232583
- Editorial: arterial stiffness, central haemodynamics and non-alcoholic fatty liver disease: links with cardiovascular risk and effects of drug treatment.Curr Vasc Pharmacol. 2018; 16: 401-404
- Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: possible molecular pathways.J Cell Physiol. 2018; 234: 223-230
- SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses.Postgrad Med. 2019; 131: 82-88
- Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure.Curr Cardiol Rep. 2019; 21: 70
- Et al; EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.N Engl J Med. 2015; 373: 2117-2128
- Et al; CREDENCE trial investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.N Engl J Med. 2019; 380: 2295-2306
- Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence.Metabolism. 2019; 96: 92-100
- Hickman A, et al.Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed-Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin, Clin Pharmacol Drug Dev2018 Nov 14 ([Epub ahead of print])
- SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan.Expert Opin Pharmacother. 2016; 17: 2073-2084
- Bone fractures with sodium-glucose co-transporter-2 inhibitors: how real is the risk?.Drug Saf. 2017; 40: 115-119
- Non-alcoholic fatty liver disease: a sign of systemic disease.Metabolism. 2017; 72: 94-108
- Fatty liver in lipodystrophy: a review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement.Metabolism. 2019; 96: 66-82
- Association of adipokines with development and progression of nonalcoholic fatty liver disease.Endoc Metab (Seoul). 2018; 33: 33-43
- Obesity as a disease.Med Clin North Am. 2018; 102: 13-33
- Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics.Metabolism. 2019; 92: 82-97
- Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: a systematic review.Metabolism. 2016; 65: 1297-1306
- Adiponectin administration prevents weight gain and glycemic profile changes in diet-induced obese immune deficient Rag1−/− mice lacking mature lymphocytes.Metabolism. 2016; 65: 1720-1730
- Omics, big data and machine learning as tools to propel understanding of biological mechanisms and to discover novel diagnostics and therapeutics.Metabolism. 2018; 87: A1-A9
- Adiponectin homolog novel osmotin protects obesity/diabetes-induced NAFLD by upregulating AdipoRs/PPARα signaling in ob/ob and db/db transgenic mouse models.Metabolism. 2019; 90: 31-43
- Non-alcoholic fatty liver disease and dyslipidemia: an update.Metabolism. 2016; 65: 1109-1123
- Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics.Metabolism. 2019; 92: 82-97
- Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: an update.World J Gastroenterol. 2015; 21: 6820-6834
- Should we expand the concept of coronary heart disease equivalents?.Curr Opin Cardiol. 2014; 29: 389-395
- Non-alcoholic fatty liver disease and risk of cardiovascular disease.Metabolism. 2016; 65: 1136-1150
- The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk.An Expert Panel Statement Metabo. 2017; 71: 17-32
- Nonalcoholic fatty liver disease and albuminuria: a systematic review and meta-analysis.Eur J Gastroenterol Hepatol. 2018; 30: 986-994
- Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis.Metabolism. 2018; 79: 64-76
- Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: a systematic review and meta-analysis.JAMA Intern Med. 2019 Jul; 1 ([Epub ahead of print])
- Treatment of Fatty Liver Disease-Time to Implement Common Sense Measures..(JAMA Intern Med)2019 Jul 1 ([Epub ahead of print])
- Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.PLoS One. 2012; 7e30555
- Canagliflozin protects against non-alcoholic steatohepatitis in type-2 diabetic rats through zinc alpha-2 glycoprotein up-regulation.Eur J Pharmacol. 2018; 828: 135-145
- Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH.Sci Rep. 2018; 8: 2362
- Effect of sodium glucose co-transporter 2 inhibitors on liver fat mass and body composition in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus.Clin Drug Investig. 2019; 39: 63141
- Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus.Hepatol Res. 2019; 49: 531-539
- Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus.Hepatol Res. 2017; 47: 1072-1078
- Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study.Obes Sci Pract. 2018; 4: 477-482
- Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes.Diabetes Obes Metab. 2018 Nov; 16 ([Epub ahead of print])
- Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease.J Diabetes Investig. 2018 Nov; 21 ([Epub ahead of print])
- Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis.Diabetes Metab Syndr Obes. 2018; 11: 835-843
- SGLT2 inhibitors and incretin agents: associations with alanine aminotransferase activity in type 2 diabetes.Diabetes Metab. 2018; 44: 493-499
- Effect of canagliflozin on liver function tests in patients with type 2 diabetes.Diabetes Metab. 2016; 42: 25-32
- Effects of canagliflozin on fatty liver indexes in patients with type 2 diabetes: a meta-analysis of randomized controlled trials.J Pharm Pharm Sci. 2018; 21: 222-235
- Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials.J Gastroenterol. 2018; 53: 140-151
- Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes.Am J Physiol Endocrinol Metab. 2017; 313: E563-E576
- Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus.Diabetes Res Clin Pract. 2018; 142: 254-263
- Dapagliflozin and empagliflozin ameliorate hepatic dysfunction among Chinese subjects with diabetes in part through glycemic improvement: a single-center, retrospective.Observ Study Diabetes Ther. 2018; 9: 285-295
- Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.Int J Clin Pract. 2019; 73e13335
- Effect of dapagliflozin on alanine aminotransferase improvement in type 2 diabetes mellitus with non-alcoholic fatty liver disease.Endocr Metab (Seoul). 2018; 33: 387-394
- Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.Diabetes Obes Metab. 2019; 21: 285-292
- Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.Diabetologia. 2018; 61: 1923-1934
- Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study.Curr Ther Res Clin Exp. 2017; 87: 13-19
- Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and α-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes.J Cell Biochem. 2018 Nov; 26 ([Epub ahead of print])
- Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes.Diabetol Metab Syndr. 2016; 8: 45
- Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial.Diabetologia. 2018; 61: 2155-2163
- Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial).Diabetes Care. 2018; 41: 1801-1808
- Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus.Dig Dis Sci. 2019 Jan; 25 ([Epub ahead of print])
- Protective effects of ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, on a non-alcoholic steatohepatitis mouse model.Yonago Acta Med. 2019; 62: 30-35
- The selective SGLT2 inhibitor Ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice.PLoS One. 2016; 11e0146337
- Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats.J Gastroenterol. 2016; 51: 1141-1149
- Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.Eur J Pharmacol. 2015; 754: 19-24
- Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects.Endocr J. 2017; 64: 363-367
- Effectiveness of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, as a second-line treatment for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus who do not respond to incretin-based therapies including glucagon-like Peptide-1 analogs and dipeptidyl Peptidase-4 inhibitors.Clin Drug Investig. 2016; 36: 313-319
- Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label.Active-Controlled Trial Diabetes Care. 2017; 40: 1364-1372
- Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: a subgroup analysis of the STELLA-LONG TERM study (3-month interim results).Endocr J. 2019; 66: 31-41
- Safety and effectiveness of ipragliflozin for type 2 diabetes in Japan: 12-month interim results of the STELLA-LONG TERM post-marketing surveillance study.Adv Ther. 2019; 36: 923-949
- Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease.Open Med (Wars). 2018; 13: 402-409
- Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus.Diabetol Metab Syndr. 2015; 7: 104
- Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study.Diabetes Obes Metab. 2018; 20: 438-442
- Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective, single-arm trial (LEAD trial).Hepatol Res. 2019; 49: 64-71
- Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models.Nutr Diabetes. 2014; 4e125
- Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH).FEBS Open Bio. 2019; 9: 643-652
- Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.Cardiovasc Diabetol. 2019; 18: 20
- Sotagliflozin: First Global Approval.Drugs. 2019; 79: 1023-1029
- CANVAS program collaborative group. Canagliflozin and cardiovascular and renal events in type 2 diabetes.N Engl J Med. 2017; 377: 644-657
- DECLARE–TIMI 58 investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes.N Engl J Med. 2019; 380: 347-357
- Analysis from the EMPA-REG OUTCOME(®) trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.Kidney Int. 2019 Mar; 21 ([Epub ahead of print])
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.Lancet Diabetes Endocrinol. 2019 Jun; 10 ([Epub ahead of print])
- Cardiorenal outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME trials: a systematic review.Rev Cardiovasc Med. 2018; 19: 41-49
Article info
Publication history
Published online: July 11, 2019
Identification
Copyright
© 2019 Elsevier Inc. All rights reserved.
